Nephrogenic fibrosing dermopathy overview: Difference between revisions
(Created page with "__NOTOC__ {{Nephrogenic fibrosing dermopathy}} {{CMG}} ==Overview== ==Overview== '''Nephrogenic fibrosing dermopathy''' or '''nephrogenic systemic fibrosis''' is a rare and s...") |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Nephrogenic fibrosing dermopathy}} | {{Nephrogenic fibrosing dermopathy}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 14:41, 28 September 2012
Nephrogenic fibrosing dermopathy Microchapters |
Differentiating Nephrogenic fibrosing dermopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Nephrogenic fibrosing dermopathy overview On the Web |
American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy overview |
Directions to Hospitals Treating Nephrogenic fibrosing dermopathy |
Risk calculators and risk factors for Nephrogenic fibrosing dermopathy overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis is a rare and serious syndrome that involves fibrosis of skin, joints, eyes, and internal organs. Its cause is not fully understood, but it seems to be associated with exposure to gadolinium (which is frequently used as a contrast substance for MRIs) in patients with severe kidney failure. It does not have a genetic basis.